|
|
EQSNews: Alzchem Group AG
/ Key words: AGM/EGM
Alzchem Group AG receives strong support from shareholders at Annual General Meeting; dividend increase to EUR 1.20 per share approved
07.05.2024 / 16:21 CET/CEST
The issuer is solely responsible for the content of this announcement.
Alzchem Group AG r... Lire le communiqué |
|
| |
|
| |
|
|
OriginalResearch: Alzchem Group AG von Sphene Capital GmbH
Einstufung von Sphene Capital GmbH zu Alzchem Group AG
Unternehmen: Alzchem Group AG
ISIN: DE000A2YNT30
Anlass der Studie: Update Report
Empfehlung: Buy
seit: 02.05.2024
Kursziel: EUR 54,60 bislang: EUR 43,40
Kursziel auf Sicht von: 24 Monate
Letzte Ratingänderung:
Analyst: Peter Thilo Hasler, CEFA
Wenn... Lire le communiqué |
|
| |
|
| |
|
|
EQSNews: Alzchem Group AG
/ Key words: Quarterly / Interim Statement
Alzchem Group AG seamlessly builds on strong business performance in 2023 with EBITDA growth of 31.7% in first quarter 2024
30.04.2024 / 07:00 CET/CEST
The issuer is solely responsible for the content of this announcement.
Alzchem... Lire le communiqué |
|
| |
|
| |
|
|
OriginalResearch: Alzchem Group AG von Sphene Capital GmbH
Einstufung von Sphene Capital GmbH zu Alzchem Group AG
Unternehmen: Alzchem Group AG
ISIN: DE000A2YNT30
Anlass der Studie: Update Report
Empfehlung: Buy
seit: 21.03.2024
Kursziel: EUR 43,40 unverändert
Kursziel auf Sicht von: 24 Monate
Letzte Ratingänderung:
Analyst: Peter Thilo Hasler, CEFA
E... Lire le communiqué |
|
| |
|
| |
|
|
EQSAdhoc: Alzchem Group AG / Key words: Expansion
Alzchem Group AG: Alzchem Group AG receives EUR 34.4 million in EU funding
15March2024 / 17:56 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation EU No 596/2014, transmitted by EQS News a service of EQS Group AG.
The issuer is solely responsible for the content of this ann... Lire le communiqué |
|
| |
|
| |
|
|
EQSMedia / 11.03.2024 / 11:15 CET/CEST
Crearene AG and Alzchem Group AG: Successful addition of creatine to dialysis patient treatments
As part of their cooperation, Alzchem Group AG and Crearene AG announced in October 2023 that a clinical study on the use of creatine in dialysis treatments had been launched. The aim is to demonstrate the technical feasibility, pa... Lire le communiqué |
|
| |
|
| |
|
|
OriginalResearch: Alzchem Group AG von Sphene Capital GmbH
Einstufung von Sphene Capital GmbH zu Alzchem Group AG
Unternehmen: Alzchem Group AG
ISIN: DE000A2YNT30
Anlass der Studie: Update Report
Empfehlung: Buy
seit: 04.03.2024
Kursziel: EUR 43,40 bislang EUR 39,50
Kursziel auf Sicht von: 24 Monate
Letzte Ratingänderung:
Analyst: Peter Thilo Hasler, CEFA
Profi... Lire le communiqué |
|
| |
|
| |
